A Reconfigured Global Supply Chain
Global pharmaceutical sourcing is being rewritten in real time. The 2025 US tariff regime on pharmaceutical imports, with rates ranging from 10% to over 240% depending on country of origin, has converted what was a slow-burn diversification debate into an urgent strategic recalibration [14]. Layered onto this is an accelerating China-plus-one shift, where multinationals and procurement-led healthcare systems are actively reducing single-country dependency for APIs, intermediates, and finished dosages [15]. Industry analysts increasingly describe the emerging structure as gated globalization: more regional, more redundant, and more politically sensitive than the cost-optimized model it replaces [15].
For Brazilian and broader Latin American stakeholders, this reset matters. Over 90% of the raw ingredients used in Brazilian pharmaceutical manufacturing are imported, primarily from China and India [10], leaving the region structurally exposed to upstream policy shocks it does not control. Within this redrawn map, India has emerged as the most credible scaled alternative for affordable, regulated-grade pharmaceutical supply [1]. For manufacturers, distributors, public-health buyers, and investors across LATAM, engaging with India is no longer a tactical procurement decision. It is a strategic positioning move.
India’s Pharmaceutical Footprint: The Numbers
India is the third-largest pharmaceutical producer globally by volume and supplies roughly 20% of the world’s generic medicines, reaching over 200 countries [2][3]. The sector was valued at approximately US$50 billion in FY 2023 to 2024 and is projected to reach US$120 to 130 billion by 2030, according to Bain & Company’s recent industry analysis [2].
The scale of regulatory accreditation is equally significant. India hosts more US FDA-approved manufacturing facilities than any country outside the United States, with over 650 such sites by Bain’s count, alongside extensive WHO-GMP, EU-GMP, and PIC/S certifications [2]. The country produces over 500 different APIs, accounting for roughly 8% of global API output and approximately 57% of WHO-prequalified APIs [4]. It is also the world’s largest vaccine manufacturer by volume, supplying 55 to 60% of UNICEF’s vaccine demand [4].
India’s pharmaceutical exports reached approximately US$30.4 billion in FY25 and grew 6.5% to US$20.48 billion in the first eight months of FY26, with Brazil identified as one of the fastest-growing destinations [4][5]. Institutional anchors such as the Indian Pharmaceutical Alliance (IPA) and Pharmexcil (the Pharmaceuticals Export Promotion Council of India) provide industry coordination and structured market-entry support.
Why LATAM Should Engage India Now
Cost competitiveness without compliance compromise
Indian manufacturing economics combine skilled labor, integrated raw-material ecosystems, low utility costs, and process maturity refined over four decades [3]. Critically, this cost structure coexists with international compliance standards rather than competing against them. The combination of US FDA, EU-GMP, and ANVISA-approved sites means LATAM buyers can access generics, APIs, and finished dosage forms at significant discounts to originator pricing without trading away regulatory credibility.
Regulatory credibility at scale
Indian sites have been audited by virtually every major regulator. The CDSCO and ANVISA Memorandum of Understanding, established in the late 2010s, formalized regulatory cooperation, and India holds the largest number of ANVISA-approved manufacturing site approvals among non-LATAM nations [6][7]. For Brazilian importers, this dramatically reduces dossier friction.
Scale and supply reliability
With over 10,000 manufacturing facilities and more than 3,000 pharmaceutical companies, India offers redundancy at the supplier level that few geographies can match [2]. Large batch capacity, vertically integrated API-to-formulation manufacturers, and multiple qualified sites for the same molecule mean LATAM buyers can build resilient, multi-source supply structures.
Innovation and the rise of Indian CDMOs
India’s contract research, development, and manufacturing (CRDMO) sector is projected to roughly double to approximately US$14 billion by 2028 [4]. Beyond commodity generics, Indian CDMOs are increasingly capable in complex generics, peptide synthesis, high-potency APIs, sterile injectables, and biosimilars. These are precisely the categories where Brazil and LATAM face the steepest import dependencies.
Brazil and LATAM: A Natural Strategic Fit
Brazil is Latin America’s largest pharmaceutical market, with valuations ranging from approximately US$35 billion to US$45 billion depending on methodology, and is projected to grow strongly through 2030 [8][9]. Generics now represent close to 38% of the Brazilian market by volume, and biosimilars have grown more than 1,500% over a three-year window according to ANVISA-linked data [10]. Yet over 90% of the raw ingredients used in Brazilian pharmaceutical manufacturing are imported, primarily from China and India [10].
This is the strategic asymmetry. Brazil and the wider LATAM region offer:
- A pharmaceutical market exceeding US$100 billion when aggregated regionally [11]
- Universal-coverage public procurement systems such as Brazil’s SUS
- A growing biosimilars and specialty-generics demand base
- Regulatory influence that radiates from ANVISA across the region
India offers:
- Manufacturing depth, API integration, and cost efficiency
- Regulatory-grade quality systems and dossier capability
- A pipeline of complex generics and biosimilars approaching Brazilian patent cliff windows
The synergy is structural. India brings supply-side strength; LATAM brings market access, regional distribution networks, and increasingly, local-finishing infrastructure.
Key Opportunity Areas
Six tactical fronts stand out for Brazilian and LATAM stakeholders:
API sourcing partnerships. Direct, qualified relationships with Indian API manufacturers reduce dependence on intermediaries, improve cost transparency, and enable long-term price stability through multi-year supply agreements.
Contract manufacturing (OEM/CMO). LATAM brand owners can leverage Indian capacity to manufacture finished dosage forms such as tablets, capsules, injectables, ophthalmics, and dermatologicals under their own labels, dramatically compressing time-to-market for portfolio expansion.
Finished dosage exports into LATAM. Indian formulations, registered through ANVISA, COFEPRIS, INVIMA, and other regional regulators, can fill gaps in public-tender pipelines and private-channel portfolios, particularly in oncology, cardiovascular, anti-diabetic, and anti-infective categories [5].
Technology transfer agreements. Indian companies are increasingly willing to license processes, transfer Drug Master Files (DMFs), and support local Brazilian manufacturing setups. This model aligns with Brazil’s policy preference for domestic production [11].
Joint ventures and local manufacturing. Approximately 25 Indian pharmaceutical companies already maintain a physical presence across LATAM, with manufacturing plants concentrated in Brazil and Mexico [6]. JV structures combining Indian technical capability with LATAM regulatory and commercial reach are accelerating.
Biosimilars and specialty generics. With Brazilian patent expirations cascading post-2025, including high-value molecules in metabolic, oncology, and autoimmune categories, Indian biosimilar developers represent a critical partnership pool [12].
Challenges and Considerations
A balanced view requires honest engagement with friction points:
Regulatory alignment. ANVISA’s GMP audit standards, CTD/eCTD documentation expectations, and stability data requirements are rigorous [7]. The CDSCO and ANVISA cooperation MOU helps, but Indian partners still need Brazil-specific dossier capability, and audit timelines can extend significantly.
Logistics and lead times. Ocean freight from Indian west-coast ports to Santos or Rio Grande creates inventory-planning implications for cold-chain and short-shelf-life products.
Pricing, tendering, and currency. Brazil’s CMED pricing controls and SUS public-tender dynamics compress margins [13]. Real to USD to INR triangulation introduces FX exposure that must be hedged or contractually structured.
Cultural and commercial cadence. Decision rhythms, contract structures, and relationship-building expectations differ between Indian exporters and LATAM buyers. Misalignment here is the most underestimated cause of failed partnerships.
IP and documentation discipline. Brazil’s 2021 Supreme Court ruling capping patents at a strict 20-year term, combined with strong INPI enforcement, makes IP due diligence non-negotiable in any technology-transfer or biosimilar arrangement [12].
A Strategic Roadmap for LATAM Companies
Rather than a transactional posture, LATAM companies should adopt a structured, phased engagement:
- Supplier qualification. Build a shortlist anchored on FDA, EU-GMP, and ANVISA audit history, financial stability, therapeutic-area fit, and DMF availability.
- Due diligence. Validate manufacturing-site inspections, audit warning letters, batch consistency, and IP cleanliness through independent regulatory consultants and on-site visits.
- Pilot before scale. Begin with a narrow product basket of two to four molecules to test commercial, regulatory, and logistical assumptions before broadening.
- Regulatory planning. Map ANVISA registration timelines into commercial planning from day one, and build dossier capability either in-house or through specialized regulatory partners.
- Long-term alliance design. Move beyond purchase orders toward multi-year supply agreements, co-development arrangements, JVs, or equity partnerships where strategic alignment justifies it.
The India and LATAM Growth Corridor
The relationship between India and LATAM is shifting from opportunistic export trade toward a genuine growth corridor, one defined by supply-chain resilience, cost efficiency, regulatory convergence, and shared interest in democratizing access to medicines. For Brazilian and LATAM companies, the question is not whether India will play a defining role in their pharmaceutical futures. It is whether they will engage early, structurally, and strategically, or play catch-up while regional competitors lock in the best partnerships.
This is precisely where Hello Pharma positions itself. Hello Pharma is a leading B2B platform for the pharmaceutical industry, engaging 140+ top pharma brands and 1,100+ companies worldwide, with visitors from over 120 countries. It functions as a focused hub for insights, learning, and industry connections across the pharma value chain.
With strong capabilities in strategic intelligence and go-to-market execution, Hello Pharma enables companies to connect with the right country, the right organization, and the right decision-makers, facilitating relevant, high-value conversations. Through curated content, expert-led interactions, and a structured ecosystem, it supports global pharmaceutical players in identifying opportunities, building partnerships, and navigating the Indian market with precision. For Brazilian and LATAM stakeholders evaluating the India corridor, Hello Pharma operates less as a service and more as a navigation layer, one designed to make the next decade of India and LATAM pharmaceutical collaboration materially more accessible.
To know more visit:
Sources
- [1] Free Press Journal, “India’s Pharma Exports Surge 6.5% To $20.48 Billion, Brazil & Nigeria Emerge As Fast-Growing Key Destinations,” January 2026. https://www.freepressjournal.in/business/indias-pharma-exports-surge-65-to-2048-billion-brazil-nigeria-emerge-as-fast-growing-key-destinations
- [2] Bain & Company, “Healing the World: A Roadmap for Making India a Global Pharma Exports Hub.” https://www.bain.com/insights/healing-the-world-a-roadmap-for-making-india-a-global-pharma-exports-hub/
- [3] ISPE, “Indian Pharmaceutical Industry: Creating Global Impact,” Pharmaceutical Engineering, March/April 2025. https://ispe.org/pharmaceutical-engineering/march-april-2025/indian-pharmaceutical-industry-creating-global-impact
- [4] India Brand Equity Foundation (IBEF), “Indian Pharmacy: Pharma Companies in India.” https://www.ibef.org/industry/pharmaceutical-india
- [5] Business Standard, “Indian MSME drugmakers likely to focus on Brazil as next growth market,” February 2026. https://www.business-standard.com/industry/news/brazil-emerges-as-key-growth-market-for-indian-msme-pharma-exporters-126022500764_1.html
- [6] PharmaBoardroom, “Indian Pharma’s Expanding LatAm Footprint,” November 2023. https://pharmaboardroom.com/articles/indian-pharmas-expanding-latam-footprint/
- [7] Tanner Pharma, “The Brazilian Pharma Market: Key information and what may change.” https://tannerpharma.com/the-brazilian-pharma-market-key-information-and-what-may-change/
- [8] Fortune Business Insights, “Brazil Pharmaceuticals Market Size, Share | Growth [2032].” https://www.fortunebusinessinsights.com/brazil-pharmaceuticals-market-114022
- [9] IMARC Group, “Brazil Pharmaceuticals Market Size, Share, Trends and Forecast 2026-2034.” https://www.imarcgroup.com/brazil-pharmaceuticals-market
- [10] International Trade Administration (US Department of Commerce), “Brazil – Healthcare Country Commercial Guide,” August 2025. https://www.trade.gov/country-commercial-guides/brazil-healthcare
- [11] Market Data Forecast, “Latin America Generic Drugs Market Size & Share, 2033.” https://www.marketdataforecast.com/market-reports/latin-america-generic-drugs-market
- [12] DrugPatentWatch, “Brazilian Pharmaceuticals 2026: The Innovation & Patent Cliff Frontier,” January 2026. https://www.drugpatentwatch.com/blog/brazilian-pharmaceuticals-a-new-frontier-in-innovation-and-medicine/
- [13] Pharmatradz, “Brazil Pharmaceutical Market Overview: Opportunities, Trends, and Challenges,” November 2025. https://pharmatradz.com/pharma-insights/brazil/the-pharmaceutical-market
- [14] Mordor Intelligence, “2025 US Pharma Tariffs: Reshaping Global Supply Chains and Strategy,” August 2025. https://www.mordorintelligence.com/signal/insights/us-tariffs-2025-reshaping-global-pharma
- [15] IntuitionLabs, “Pharma Tariffs 2026: Supply Chain & Manufacturing Impacts,” 2026. https://intuitionlabs.ai/articles/pharma-tariffs-2026-supply-chain-onshoring
